MP74-11 PRE-SURGICAL EXPRESSED PROSTATIC SECRETION BIOMARKER PERFORMANCE IN THE DETECTION OF GLEASON UPGRADING IN PROSTATE CANCER

Autor:	Steven J. Smith, Kristina Wittig, Timothy Wilson, Mark H. Kawachi, David Smith, Clayton Lau, Jonathan Yamzon
Rok vydání:	2014
Předmět:	PCA3 medicine.medical_specialty medicine.diagnostic_test business.industry Urology urologic and male genital diseases medicine.disease Prostate cancer Linear regression Biopsy Medicine Biomarker (medicine) In patient Cumulative incidence sense organs skin and connective tissue diseases business
Zdroj:	Journal of Urology. 191
ISSN:	1527-3792 0022-5347
Popis:	was followed by an inverse change of equal or greater magnitude. To determine clinically meaningful variation, we used an increase of 1ng/ mL that was followed by a decrease of equal magnitude across measurements. The association between each measure of variation and number of PSA measurements was assessed using linear regression. RESULTS: In 541 men studied, the cumulative incidence of discontinuing AS for definitive treatment within 5 years was 13%. Among 251(46%) patients who reached a PSA of 7ng/mL, 186(74%) decreased from this threshold at least once. 417 (77%) patients reached a PSA of 4ng/mL but their PSA measurements fluctuated around this threshold less often. In patients who reached a PSA of 4ng/ mL or 7ng/mL, the number of PSA measurements was significantly associated with the frequency of variation across each threshold (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1f4075b901d07a5f8fd4e8359cb54ba7 https://doi.org/10.1016/j.juro.2014.02.2344 Zobrazit plný text záznamu